VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, 3, [4], 5 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 06:34:12 08/04/06 Fri
Author: Sheller, Ludwig & Sheller
Subject: Defective Drugs: Floxin: liver failure and death
In reply to: Daiichi Pharmaceutical Co., Ltd. 's message, "Hoover's coverage by Rachel Meyer" on 06:06:09 08/04/06 Fri

Defective Drugs: Floxin: liver failure and death
Floxin is manufactured by Ortho-McNeil Corporation. Floxin is an antibiotic in the class of drugs known as fluoroquinolones which are synthetic antimicrobial agents that were modeled after nalidixic acid, a non-flourinated quinolone antibiotic. Nalidixic acid was approved by the FDA in 1963 for the treatment of urinary tract infections. It is rapidly absorbed after oral administration and is excreted into the urine in bactericidal concentrations. Nalidixic acid had several limitations in that it has a narrow spectrum of activity and microorganisms easily developed a resistance to it.

During the 1980's, modifications to this drug were made. New fluoroquinolone antimicrobials were developed and put on the fast track for FDA approval without the benefit of adequate premarket testing to accurately determine the probability of certain side effects within the general population. After gaining FDA approval, the new fluoroquinolones were aggressively marketed by the manufacturers. In doing so, the manufacturers failed to provide adequate warnings to the prescribing physicians of the dangers, risks and adverse side effects associated with fluoroquinolones.

Severe adverse reactions associated with fluoroquinolones, including Floxin are:

Fatalities

Central nervous system (CNS) adverse reactions including convulsions, seizures, visual disturbances, sleep disorders, agitation, insomnia, headaches and dizziness

Cardiovascular adverse reactions including prolongation of the Qtc interval which can potentially lead to ventricular arrhythmias and sudden cardiac death

Hematologic adverse reactions including anemia, leukopenia, increased and decreased prothrombin time and increased and decreased platelet counts

Immunologic adverse reactions including skin manifestations, allergic reaction, fatal hypersensitivity vasculitis and hypatotaxoicity

Liver disease and elevated liver enzymes

Gastrointestinal adverse reactions including colitis, abdominal pain, nausea and vomiting
Compounding the problem is that there are numerous drugs which should not be taken in combination with fluoroquinolones. There are increased risks of injury when fluoroquinolones are taken in combination with corticosteriods (e.g.: Prednisone, Flovent, Nasarel, Azmacort, Advair Disku, Methylprednisolone Dospak, Elocon Cream, Desoximetasone Cream, and Sterapred) and when taken in combinations with non-steroidal anti-inflamatory drugs (NSAIDs) (e.g.: Motrin, Pamprin, Aleve, Advil, and Ibuprofen, among others). Physicians are frequently not aware of these contraindications and prescribe dangerous combinations of drugs which cause severe injuries to their patients. Physicians may also not be able to identify that their patient is suffering an adverse reaction and instruct them to continue to take more fluoroquinolones resulting in very serious and perhaps preventable injuries.

Confidential Questionnaire
Transmission of information on this Web site is not intended to create, and receipt does not constitute, an attorney-client relationship between you and the firm.

*Items are required. All others are optional. Website - http://www.sheller.com/Practice.asp?PracticeID=28 Contact Us

Philadelphia Office
1528 Walnut Street
3rd Floor
Philadelphia, PA 19102
Phone: (215) 790-7300
Toll free: (800) 883-2299
Fax: 215-546-0942
sasheller@sheller.com New Jersey Office
One Greentree Centre
Suite 201
Route 73 & Greentree Road
Marlton, NJ 08053
Phone: (856) 988-5590
Toll free: (800) 883-2299
Fax: 856-596-8359
sasheller@sheller.com


If you have a legal question for Sheller, Ludwig & Sheller, please complete the form below. All initial case evaluations are free. Transmission of information on this Web site is not intended to create, and receipt does not constitute, an attorney-client relationship between you and the firm.

*Items are required.

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Replies:

[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.